Evidence map›Paper›PMID 27446933›Full record

ArticleFrontiers in cardiovascular medicine2016

Clinical Genetic Testing for the Cardiomyopathies and Arrhythmias: A Systematic Framework for Establishing Clinical Validity and Addressing Genotypic and Phenotypic Heterogeneity.

John Garcia, Jackie Tahiliani, Nicole Marie Johnson, Sienna Aguilar, Daniel Beltran, Amy Daly, Emily Decker, Eden Haverfield, Blanca Herrera, Laura Murillo and 2 more

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. Review
  4. Article
  5. Review
  6. A Person-Centered Approach to Cardiovascular Genetic Testing.Cold Spring Harbor perspectives in medicine · 2020
    Review
  7. Article
  8. Brugada Syndrome: Oligogenic or Mendelian Disease?International journal of molecular sciences · 2020
    Review
  9. Review
  10. Article
  11. Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.Genetics in medicine : official journal of the American College of Medical Genetics · 2017
    Article
  12. Review
  13. Review
  14. Pathogenesis and management of Brugada syndrome.Nature reviews. Cardiology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

John GarciaInvitae Corporation , San Francisco, CA , USA.
Jackie TahilianiInvitae Corporation , San Francisco, CA , USA.
Nicole Marie JohnsonInvitae Corporation , San Francisco, CA , USA.
Sienna AguilarInvitae Corporation , San Francisco, CA , USA.
Daniel BeltranInvitae Corporation , San Francisco, CA , USA.
Amy DalyInvitae Corporation , San Francisco, CA , USA.
Emily DeckerInvitae Corporation , San Francisco, CA , USA.
Eden HaverfieldInvitae Corporation , San Francisco, CA , USA.
Blanca HerreraInvitae Corporation , San Francisco, CA , USA.
Laura MurilloInvitae Corporation , San Francisco, CA , USA.
Keith NykampInvitae Corporation , San Francisco, CA , USA.
Scott TopperInvitae Corporation , San Francisco, CA , USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in DNA sequencing have made large, diagnostic gene panels affordable and efficient. Broad adoption of such panels has begun to deliver on the promises of personalized medicine, but has also brought new challenges such as the presence of unexpected results, or results of uncertain clinical significance. Genetic analysis of inherited cardiac conditions is particularly challenging due to the extensive genetic heterogeneity underlying cardiac phenotypes, and the overlapping, variable, and incompletely penetrant nature of their clinical presentations. The design of effective diagnostic tests and the effective use of the results depend on a clear understanding of the relationship between each gene and each considered condition. To address these issues, we developed simple, systematic approaches to three fundamental challenges: (1) evaluating the strength of the evidence suggesting that a particular condition is caused by pathogenic variants in a particular gene, (2) evaluating whether unusual genotype/phenotype observations represent a plausible expansion of clinical phenotype associated with a gene, and (3) establishing a molecular diagnostic strategy to capture overlapping clinical presentations. These approaches focus on the systematic evaluation of the pathogenicity of variants identified in clinically affected individuals, and the natural history of disease in those individuals. Here, we applied these approaches to the evaluation of more than 100 genes reported to be associated with inherited cardiomyopathies and arrhythmias including hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular dysplasia or cardiomyopathy, long QT syndrome, short QT syndrome, Brugada, and catecholaminergic polymorphic ventricular tachycardia, and to a set of related syndromes such as Noonan Syndrome and Fabry disease. These approaches provide a framework for delivering meaningful and accurate genetic test results to individuals with hereditary cardiac conditions.

Indexed as

arrhythmiasARVD/Ccardiomyopathiescurationgenetic testing

Identifiers

PMID27446933
PMCPMC4921949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.